GlycoMimetics Accounts Payable

GlycoMimetics (GLYC) currently reports a accounts payable of $2.5M as of June 2026. That compares with $1.6M in the prior-year period — up 54.2% year over year. Use the charts on this page to explore GlycoMimetics's accounts payable history and peer comparisons.

GlycoMimetics's accounts payable increased from $1.6M to $2.5M — a 54.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GlycoMimetics reported $2.5M in accounts payable as of June 2026. That compares with $1.6M in the prior-year period — up 54.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $2.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for GlycoMimetics, and consider following GLYC for alerts when major investors trade the stock.

GlycoMimetics is classified in the Healthcare sector. On accounts payable, it currently shows $2.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GLYC with unrelated industries.